Since APL with FIP1L1::RARA has demonstrated different sensitivities to ATRA, combined chemotherapy rather than differentiation induction therapy may be the appropriate treatment for APL with FIP1L1::RARA with no sensitivity to ATRA. Here, FASLG is linked to acute promyelocytic leukemia.